Developing novel 3D-printed personalized medicines and medical devices
We are looking for new students to start a PhD in the development of innovative personalised medicines and medical devices prepared by three-dimensional printing. Depending on the skill and the interest of the candidates, the selected PhD students will be involved in multiple research projects around pharmaceutical 3D printing, including digital pharmacy, pharmacokinetic prediction, therapeutic drug monitoring and artificial intelligence for manufacturing optimization.
Developing novel medicines targeted at the human gut microbiome
Cutting-edge research is highlighting how important the human microbiome is for health. As fundamental science characterizing the complex functions and processes of microbes emerges, many opportunities for microbiome-targeted therapeutics are being presented. Numerous diseases could be prevented and treated through targeted delivery of small molecules, biologics, or probiotics to the human microbiome. Diseases that have been linked with the gut microbiome include cardiovascular disease, diabetes mellitus, colon cancer, Parkinson’s disease, autism spectrum disorder, and depression.
Using Machine Learning to develop novel drug delivery systems
Machine learning has revolutionised numerous fields from self-driving technologies to aeronautics and drug discovery, yet its impact remains under-explored in the domain of drug formulation development – an area marked by extensive resource and labour investment. This project aims to harness machine learning to create sophisticated models that can fast-track and fine-tune the development of ground-breaking drug delivery systems. The project will explore the potential benefits of machine learning in refining the formulation development process and elevating advanced development techniques like additive manufacturing. The selected applicant will receive extensive training across the entire project spectrum, focusing on how machine learning can effectively utilise laboratory results to influence future breakthroughs.
Tackling health inequity in pharmaceuticals
Research has been increasingly highlighting the disparities in the investigation of gender-specific responses to medicines. It has been observed that substances thought to be inactive in medications have biological effects that differ between genders. These findings are the focus of this project, which is aimed at exploring and harnessing such variations. The overarching aim is the addressing and mitigation of these disparities, advancing the field towards more equitable healthcare provision.